Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Gregory F. Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Carolina Reyes, PhD, Kenneth Wilhelm, MD, Tania Krivasi, MSc, David L. Veenstra, PharmD, PhD

Blood (2016) 128 (22): 3605.

https://doi.org/10.1182/blood.V128.22.3605.3605

Published: 2016

Journal Articles

Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Carolina Reyes, PhD, Gregory Gazauskas, PhD, Ursula Becker, MSc, Santiago Moreno, David L. Veenstra, PharmD, PhD

Blood (2014) 124 (21): 1324.

https://doi.org/10.1182/blood.V124.21.1324.1324

Published: 2014

Journal Articles

Risk-Benefit Trade-Off of Pediatric-Inspired Versus Hyper-CVAD Protocols for Philadelphia Negative Acute Lymphocytic Leukemia (ALL) in Adolescents and Young Adults: A Modeling Analysis

Gregory F. Guzauskas, MSPH, PhD, Kathleen F. Villa, MS, Trudy F. Vanhove, MD PhD MBA, David L. Veenstra, PharmD, PhD

Blood (2014) 124 (21): 1281.

https://doi.org/10.1182/blood.V124.21.1281.1281

Published: 2014

Journal Articles

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

Gregory M. Cooper, Julie A. Johnson, Taimour Y. Langaee, Hua Feng, Ian B. Stanaway, Ute I. Schwarz, Marylyn D. Ritchie, C. Michael Stein, Dan M. Roden, Joshua D. Smith, David L. Veenstra, Allan E. Rettie, Mark J. Rieder

Blood (2008) 112 (4): 1022–1027.

https://doi.org/10.1182/blood-2008-01-134247

Published: 2008

Includes: Supplemental data

Journal Articles

CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians

Allan E. Rettie, Guoying Tai, David L. Veenstra, Fred M. Farin, Sengkeo Srinouanprachan, Yvonne S. Lin, Kenneth E. Thummel, Ronald N. Hines

Blood (2003) 101 (7): 2896.

https://doi.org/10.1182/blood-2002-11-3452

Published: 2003

NARROW

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Risk-Benefit Trade-Off of Pediatric-Inspired Versus Hyper-CVAD Protocols for Philadelphia Negative Acute Lymphocytic Leukemia (ALL) in Adolescents and Young Adults: A Modeling Analysis

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians

Email alerts

ASH Publications

American Society of Hematology

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Risk-Benefit Trade-Off of Pediatric-Inspired Versus Hyper-CVAD Protocols for Philadelphia Negative Acute Lymphocytic Leukemia (ALL) in Adolescents and Young Adults: A Modeling Analysis

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only